Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 3/20 | 0.45 |
| ▸ | DRD2 | P14416 | 2/20 | 0.45 |
| ▸ | HTR1A | P08908 | 2/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17980208 | 1.00 | DRD3 (0.45) | DRD3DRD2HTR1AGRIN1GRIN2A | |
| SCHEMBL17980211 | 1.00 | DRD3 (0.45) | DRD3DRD2HTR1AGRIN1GRIN2A | |
| SCHEMBL17979982 | 1.00 | DRD3 (0.45) | DRD3DRD2HTR1AGRIN1GRIN2A | |
| SCHEMBL17980092 | 0.96 | DRD3 (0.46) | DRD3DRD2HTR1A | |
| SCHEMBL20031167 | 0.96 | DRD3 (0.46) | DRD3DRD2HTR1A | |
| SCHEMBL17980127 | 0.96 | DRD3 (0.46) | DRD3DRD2HTR1A | |
| SCHEMBL17980091 | 0.96 | DRD3 (0.46) | DRD3DRD2HTR1A | |
| SCHEMBL17980182 | 0.96 | DRD3 (0.46) | DRD3DRD2HTR1A | |
| SCHEMBL17980066 | 0.96 | DRD3 (0.46) | DRD3DRD2HTR1A | |
| SCHEMBL17980149 | 0.96 | DRD3 (0.46) | DRD3DRD2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111925360-B | 1-heterocyclylisochromanyl compounds and analogs for the treatment of CNS disorders | 赛诺维信制药公司 | 2024-03-22 | — | — | CN | disclosed |
| EP-4046995-B1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC (US) | 2023-09-13 | — | — | EP | disclosed |
| EP-4046995-A1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | Sunovion Pharmaceuticals Inc. (US) | 2022-08-24 | — | — | EP | disclosed |
| US-20220185799-A1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2022-06-16 | — | — | US | disclosed |
| US-11192885-B2 | 1-heterocyclyl isochromanyl compounds and analogs for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2021-12-07 | — | — | US | disclosed |
| CN-111925360-A | 1-heterocyclyl isochroman compounds and analogs for the treatment of CNS disorders | 赛诺维信制药公司 | 2020-11-13 | — | — | CN | disclosed |
| CN-107531674-B | 1-heterocyclyl isochroman compounds and analogs for the treatment of CNS disorders | 赛诺维信制药公司 | 2020-07-31 | — | — | CN | disclosed |
| US-10336732-B2 | 1-heterocyclyl isochromanyl compounds and analogs for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180093974-A1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2018-04-05 | — | — | US | disclosed |
| US-20180093974-A1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2018-04-05 | — | — | US | disclosed |
| US-9856238-B2 | 1-heterocyclyl isochromanyl compounds and analogs for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2018-01-02 | — | — | US | disclosed |
| EP-3256466-A1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | Sunovion Pharmaceuticals Inc. (US) | 2017-12-20 | — | — | EP | disclosed |
| US-20170001987-A1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | SUMITOMO PHARMA AMERICA, INC. | 2017-01-05 | — | — | US | disclosed |
| US-20170001987-A1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | SUMITOMO PHARMA AMERICA, INC. | 2017-01-05 | — | — | US | disclosed |
| WO-2016130796-A1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2016-08-18 | — | — | WO | disclosed |
| WO-2016130796-A1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2016-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170001987-A1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | CNR1, HCRTR1, CNR2 | DRD3 240/4885DRD2 212/4885HTR1A 29/4885 |
| US-11192885-B2 | 1-heterocyclyl isochromanyl compounds and analogs for treating CNS disorders | CNR1, HCRTR1, CNR2 | DRD3 240/4885DRD2 212/4885HTR1A 29/4885 |
| US-20180093974-A1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | CNR1, HCRTR1, CNR2 | DRD3 240/4885DRD2 212/4885HTR1A 29/4885 |
| US-20220185799-A1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | CNR1, HCRTR1, CNR2 | DRD3 240/4885DRD2 212/4885HTR1A 29/4885 |
| US-10336732-B2 | 1-heterocyclyl isochromanyl compounds and analogs for treating CNS disorders | CNR1, HCRTR1, CNR2 | DRD3 240/4885DRD2 212/4885HTR1A 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.